



PharmAust secures core patent in Japan

6 June 2017 – Perth, Australia: PharmAust (ASX: PAA), a clinical-stage oncology company, is pleased to announce the grant of a core patent in Japan.

The patent (No. 2015-500717), entitled “Kinase Inhibitors for the Treatment of Cancer”, claims the use of aminoacetonitrile derivatives as potent kinase inhibitors for the treatment of cancer and provides the company with protection for this intellectual property until 2033.

‘Aminoacetonitrile derivatives’ include the Novartis Animal Health/Elanco compound Monepantel (MPL), which PharmAust has patented for cancer applications and is being evaluated in clinical trials.

Dr Richard Hopkins, PharmAust’s CEO commented, “We are delighted with the allowance of this “Method of Use” patent that further extends PharmAust’s core intellectual property in another key market. We have now secured granted patents for this family in Australia, China, the US and Japan, providing us strong strategic protection for this class of molecule.”

Enquiries:

Dr Richard Hopkins
CEO
Tel: 0405 656 868
rhopkins@pharmaust.com

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
raston@pharmaust.com

About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, a contract synthetic drug manufacturer forecast to generate Aus\$3m in revenues in 2017 at a CAGR of 28%.

PAA’s lead drug candidate is Monopantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trial.

About NewSouth Innovations (NSi): NSI are a commercialisation company responsible for the protection and management of Intellectual Property (IP) developed at the University of New South Wales (UNSW). PharmAust acknowledges that the IP referred to in this announcement was assigned to Pitney Pharmaceuticals, a subsidiary of PharmAust, from the University of New South Wales in 2013